Cambrian Biopharma

Amplifier Therapeutics is a biopharmaceutical company dedicated to developing novel therapies targeting AMP-activated protein kinase (AMPK), a key regulator of cellular energy balance. The company's focus is on treating age-related disorders, including metabolic conditions, cardiovascular diseases, kidney diseases, and certain types of cancer, by activating AMPK to restore normal cellular function.

Vita Therapeutics is a cell engineering company focused on developing innovative treatments for debilitating neuromuscular diseases and cancers. The company leverages induced pluripotent stem cell technology to create specific cell types intended to replace defective cells in patients. By targeting the underlying causes of diseases, Vita Therapeutics aims to provide truly curative cellular medicines that can significantly improve patient outcomes.

Oviva Therapeutics is a company dedicated to enhancing women's health and well-being as they age through innovative biomedical research and the development of therapeutics. The company focuses on improving ovarian function to extend the health span of women, addressing specific aspects of female physiology. By engaging with scientists and clinicians, Oviva Therapeutics aims to advance clinical development and drive meaningful progress in treatments that target the challenges associated with ovarian aging. Through advocacy and research, the company seeks to transform the experience of aging for women, ensuring they receive effective solutions tailored to their unique health needs.

Vita Therapeutics is a cell engineering company focused on developing innovative treatments for debilitating neuromuscular diseases and cancers. The company leverages induced pluripotent stem cell technology to create specific cell types intended to replace defective cells in patients. By targeting the underlying causes of diseases, Vita Therapeutics aims to provide truly curative cellular medicines that can significantly improve patient outcomes.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

Samsara Therapeutics, founded in 2018 with operations across Europe and San Diego, is a biopharmaceutical company dedicated to discovering and developing therapeutics for age-related diseases and unmet medical needs. Its proprietary platform focuses on identifying and validating compounds that extend healthy lifespan by targeting fundamental aging processes such as proteostasis and autophagy. The company aims to create novel treatments for rare genetic and neurodegenerative diseases through its pipeline, which involves compound identification, chemical optimization, and in vivo validation across various species.